---
title: "Azilect: Technion Research and Clinical Development"
description: "Technion researchers John Finberg and Moussa Youdim developed rasagiline with Teva, later marketed as Azilect. In the 2009 ADAGIO trial, the primary delayed-start criteria were met at 1 mg daily but not at 2 mg."
url: "https://hasbara.co.il/resources/israeli-pharmaceutical-industry-teva-and-generic-drugs/the-clinical-development-of-azilect"
type: "resource-page"
locale: "en"
categories: ["Israeli Pharmaceutical Industry: Teva and Generic Drugs"]
---

# Azilect: Technion Research and Clinical Development

*Technion researchers John Finberg and Moussa Youdim developed rasagiline with Teva, later marketed as Azilect. In the 2009 ADAGIO trial, the primary delayed-start criteria were met at 1 mg daily but not at 2 mg.*

Azilect is the brand name for rasagiline, a Parkinson’s disease medicine developed through work by Technion researchers John Finberg and Moussa Youdim with Teva. The FDA approved the drug in 2006. In the later ADAGIO study, the trial’s prespecified criteria for a possible disease-modifying effect were met at 1 mg daily but not at 2 mg.

## Technion research moved into drug development

Finberg and Youdim worked on rasagiline at the Technion’s Rappaport Faculty of Medicine and collaborated with Teva on its development. The Technion’s account describes the researchers’ work and the drug’s route from research to treatment. Its [history of rasagiline and Azilect](https://www.technion.ac.il/en/blog/2022/03/from-tehran-to-haifa-from-selegiline-to-azilect/) explains the collaboration; the [Technion technology-transfer foundation](https://trdf.technion.ac.il/en/about-services/) describes how academic research connects with industry.

A drug candidate must pass clinical trials and regulatory review before it can be marketed. FDA approval made rasagiline a treatment for Parkinson’s disease; it did not establish that the drug cures the disease.

## What ADAGIO measured

Published in 2009, ADAGIO was an 18-month, double-blind, placebo-controlled delayed-start trial involving 1,176 people with untreated Parkinson’s disease. Participants received rasagiline at 1 mg or 2 mg daily from the start, or placebo for 36 weeks followed by rasagiline for the remaining 36 weeks. The study tested whether early treatment met three prespecified criteria: slower worsening during the first phase, no catch-up after the delayed-start group began treatment, and a difference between groups at the end.

The [ADAGIO trial report in the New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa0809335) reported that all three criteria were met for 1 mg daily. For 2 mg, early treatment slowed the measured worsening in the first phase, but the full set of criteria was not met. The results therefore differed by dose; the study did not establish a dose-independent claim that rasagiline slows Parkinson’s disease progression. For a second Israeli university research example, see [Copaxone’s development from Weizmann research](https://hasbara.co.il/resources/israeli-pharmaceutical-industry-teva-and-generic-drugs/the-breakthrough-development-and-global-success-of-copaxone).

## Pages

- [From S.L.E. to Teva: The Industry's Early History](/resources/israeli-pharmaceutical-industry-teva-and-generic-drugs/the-early-history-and-consolidation-of-teva-pharmaceuticals.md)
- [Eli Hurvitz and Teva's Global Expansion](/resources/israeli-pharmaceutical-industry-teva-and-generic-drugs/eli-hurvitz-and-the-globalization-of-teva-pharmaceuticals.md)
- [Teva's API Business and the Global Drug Supply](/resources/israeli-pharmaceutical-industry-teva-and-generic-drugs/teva-active-pharmaceutical-ingredients-and-the-global-drug-supply.md)
- [Copaxone: Weizmann Research to Multiple Sclerosis Treatment](/resources/israeli-pharmaceutical-industry-teva-and-generic-drugs/the-breakthrough-development-and-global-success-of-copaxone.md)
- [Drug Approval and Manufacturing in Israel](/resources/israeli-pharmaceutical-industry-teva-and-generic-drugs/fda-approval-of-kfar-saba-and-israeli-drug-exports.md)
- [Israeli Pharmaceutical Research, Manufacturing and Exports](/resources/israeli-pharmaceutical-industry-teva-and-generic-drugs/academic-industrial-collaboration-in-israeli-drug-discovery.md)

## Sources

- [technion.ac.il](https://www.technion.ac.il/en/blog/2022/03/from-tehran-to-haifa-from-selegiline-to-azilect/)
- [trdf.technion.ac.il](https://trdf.technion.ac.il/en/about-services/)
- [nejm.org](https://www.nejm.org/doi/full/10.1056/NEJMoa0809335)
